Atypical Orofacial Pain Diagnostics and Differentiation.
1 other identifier
interventional
150
1 country
1
Brief Summary
Orofacial pain is diagnosed for more than 1.9 percent of general population and for 0.3 percent origin of the facial pain is unknown. Commonly atypical facial pain is treated as a neurological condition without an emotional or psychiatric evaluation. Since atypical pain and mood affective disorders can be related, patients do not receive proper care for this condition. The aim of this study is to evaluate the relationship between atypical facial pain syndrome and affective mood disorders. We aim to assess patients' with no diagnosed organic pathology tendency towards anxiety, depression, sleep disorders and one of big five personality traits through self-rating questionnaires. We will compare the gathered data with biosensors from iMotions software.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 21, 2021
CompletedStudy Start
First participant enrolled
February 27, 2021
CompletedFirst Posted
Study publicly available on registry
March 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 22, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2021
CompletedMarch 1, 2021
February 1, 2021
5 months
February 21, 2021
February 25, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (11)
Visual analog scale
Patients evaluate their spontaneous episodic pain before assessing self-evaluating questionnaires. Patient pain will be assessed using a visual analogue scale of 0-10, zero being no pain, ten being an unbearable/unimaginable pain. The higher score may lead to a possibilty of developing mood disorders.
Assessment score gathered once (Day 1)
Hospital anxiety and depression scale
The Hospital anxiety and depression scale is a fourteen-item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.
Assessment score gathered once (Day 1)
Pittsburgh sleep quality index
The Pittsburgh Sleep Quality Index contains 19 self-rated questions which measures seven aspects of sleep: (1) subjective sleep quality, (2) sleep latency, (3) sleep duration, (4) habitual sleep efficiency, (5) sleep disturbances, (6) use of sleeping medication, and (7) daytime dysfunction. The 19 self-rated items are combined to form seven component scores, each of which has a range of 0-3 points (0 indicates no difficulty, while 3 indicates severe difficulty). The seven component scores are then summed to yield one global score, with a range of 0-21 points (0 indicating no difficulty, and 21 indicating severe difficulties in all the seven areas of sleep quality).
Assessment score gathered once (Day 1)
Big Five personality traits
Big five personality traits questionnaire is a 25-item questionnaire compiled from Goldberg et al. 1999. Respondent chooses between a pair of adjectives and chooses an according score from one to seven. All personality dimensions are evaluated separately from specific pairs of adjectives and sum of these pairs scores. Lithuanian version is adapted from A.Bunevičius (2006).
Assessment score gathered once (Day 1)
Galvanic skin response. Valence
Galvanic skin response peaks (countable) either total or within positive, negative and neutral condition valence.
Assessment score gathered once (Day 1)
Galvanic skin response. Amplitude
Galvanic skin response is measured in microsiemens. Sudden rise in skin conductivity is called a peak. Peak amplitudes (in microsiemens) will be recorded and analysed. Average amplitude of peaks, either total or within positive, negative and neutral valence.
Assessment score gathered once (Day 1)
Galvanic skin response. Peaks/minute
Peaks/minute (normalized measure) either total or within positive, negative and neutral valence.
Assessment score gathered once (Day 1)
Facial expression analysis. Duration of positive valence.
Facial expression analysis determines the respondents' valence (negative, positive or neutral). The duration of positive valence (more than 30 percent threshold) will be assessed seconds.
Assessment score gathered once (Day 1)
Facial expression analysis. Duration of negative valence.
Facial expression analysis determines the respondents' valence (negative, positive or neutral), the duration of negative valence (less than 30 percent threshold) will be assessed in seconds.
Assessment score gathered once (Day 1)
Facial expression analysis. Duration of neutral valence.
Facial expression analysis determines the respondents' valence (negative, positive or neutral). The duration of neutral valence (from -30 percent to 30 percent threshold) will be assessed in seconds.
Assessment score gathered once (Day 1)
Facial expression analysis. Total duration.
Facial expression analysis determines the respondents' valence (negative, positive or neutral). A total duration of the record (measuring time in seconds) will be used.
Assessment score gathered once (Day 1)
Secondary Outcomes (3)
Heart rate
Assessment score gathered once (Day 1)
Facial expression analysis (raw data)
Assessment score gathered once (Day 1)
Facial expression analysis threshold
Assessment score gathered once (Day 1)
Study Arms (2)
Atypical facial pain group
EXPERIMENTALPatients with clinally diagnosed G50.1 - atypical pain condition after all necessary diagnostic measures are taken to exclude a clear organic pathology (multiple diagnostic tests including MRI, CT and consultations from other specialists). Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
Maxillofacial fracture pain group
ACTIVE COMPARATORPatients with maxillofacial fracture (S02.3, S02.4, S02.6.) will be subjected into control group. Patients included in this study will undergo self-evaluating questionnaires and objective data analysis with facial expression analysis, galvanic skin response and heart rate. All tests are performed in one visit which will last up to an hour.
Interventions
Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
Eligibility Criteria
You may qualify if:
- Adult patients (18-70years old) who were clinically diagnosed with atypical pain syndrome (G50.1).
- Patients who accepted terms of this research and has signed informed consent form.
- Patients were not previously diagnosed with a psychiatric disorder.
You may not qualify if:
- A potential participant of the study is not able to comprehend information regarding this study's protocol in both written and verbal forms or fails/refuses to sign an informed consent form.
- Patients who have a diagnosed organic pathology causing orofacial pain.
- Patients who are diagnosed with systemic diseases which may interfere with the study or patients who present with head or neck oncology pathologies.
- Patients who were previously diagnosed with a psychiatric disorder.
- Control group Control group will consist of patients who were subjected to maxillofacial fracture (any jaw unilateral fracture). These patients will be involved in this study if they are hospitalized/or have visited Lithuanian University of Health Sciences hospital Kaunas Clinics Department of maxillofacial surgery.
- Adult patients (18-70year old) who have been diagnosed with orofacial pain due to jaw fracture (S02.3, S02.4, S02.6).
- Patients who have signed an informed consent form.
- Patients who were not previously diagnosed with a psychiatric disorder.
- A potential participant of the study is not able to comprehend information regarding this study's protocol in both written and verbal forms or fails/refuses to sign an informed consent form.
- Patients who are diagnosed with systemic diseases which may interfere with the study or patients who present with head or neck oncology pathologies.
- Patients who were previously diagnosed with a psychiatric disorder.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Lithuanian University of Health Sciences Kaunas Clinics
Kaunas, Lithuania
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Administrator in Lithuanian University of Health Sciences Kaunas Clinics, Dentist, Oral Surgeon
Study Record Dates
First Submitted
February 21, 2021
First Posted
March 1, 2021
Study Start
February 27, 2021
Primary Completion
July 22, 2021
Study Completion
August 1, 2021
Last Updated
March 1, 2021
Record last verified: 2021-02